Literature DB >> 1728545

Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-alpha and interleukin 6 in serum.

S Furukawa1, T Matsubara, K Yone, Y Hirano, K Okumura, K Yabuta.   

Abstract

It has been reported that tumour necrosis factor-alpha (TNF-alpha) is capable of inducing vascular injury, and interleukin 6 (IL-6) of inducing production of acute phase proteins and the maturation of megakaryocytes. Kawasaki disease (KD) is a systemic vasculitis with severe inflammation. We investigated whether TNF-alpha and IL-6 activities in serum from patients with KD differs from those in anaphylactoid purpura (AP) and measles. Serum TNF-alpha levels were measured by a sandwich enzyme immunoassay and IL-6 activities in serum were assessed by a colorimetric assay. Both KD and AP patients but not patients with measles had increased serum TNF-alpha levels during the acute stage. With respect to IL-6, patients with KD and measles, but not AP, had increased IL-6 activities in serum during the acute stage. IL-6 activities in serum of KD patients correlated with serum C-reactive protein levels and correlated to some extent with maximum platelet counts during the course of illness. These results suggest that KD differs from AP and measles regarding both cytokines. The combination of TNF-alpha, which may be responsible for severe vascular injury, and IL-6, which may be responsible for severe inflammation, may play an important role in acute KD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1728545     DOI: 10.1007/bf02073890

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  16 in total

1.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

2.  Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions.

Authors:  T Matsubara; S Furukawa; K Yabuta
Journal:  Clin Immunol Immunopathol       Date:  1990-07

3.  Circulating interleukin-1 beta in patients with Kawasaki disease.

Authors:  C P Maury; E Salo; P Pelkonen
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

4.  The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illnesses.

Authors:  Y Ueno; N Takano; H Kanegane; T Yokoi; A Yachie; T Miyawaki; N Taniguchi
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

5.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

6.  Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies.

Authors:  T Matsuda; T Hirano; T Kishimoto
Journal:  Eur J Immunol       Date:  1988-06       Impact factor: 5.532

7.  Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.

Authors:  J S Pober; M P Bevilacqua; D L Mendrick; L A Lapierre; W Fiers; M A Gimbrone
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

8.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.

Authors:  M P Bevilacqua; J S Pober; G R Majeau; W Fiers; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

9.  Pathology of the heart in Kawasaki disease.

Authors:  H Fujiwara; Y Hamashima
Journal:  Pediatrics       Date:  1978-01       Impact factor: 7.124

10.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  19 in total

1.  Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways.

Authors:  Kazuki Murakami; Chiaki Suzuki; Fujio Kobayashi; Atsushi Nakano; Akihiro Fujii; Kaoru Sakai; Teruaki Imada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-31       Impact factor: 3.000

Review 2.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

Review 4.  Classification of the vasculitides: are they clinically useful?

Authors:  Ana M Bertoli; Graciela S Alarcón
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

5.  Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.

Authors:  Haruyuki Makata; Takashi Ichiyama; Ryutaro Uchi; Tsuyoshi Takekawa; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

6.  Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

Authors:  M Gupta; G J Noel; M Schaefer; D Friedman; J Bussel; R Johann-Liang
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

7.  Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy?

Authors:  G Rostoker; J C Rymer; G Bagnard; M Petit-Phar; M Griuncelli; Y Pilatte
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

8.  Carbamazepine-induced thrombocytopenia and leucopenia complicated by Henoch-Schönlein purpura symptoms.

Authors:  K Kaneko; J Igarashi; Y Suzuki; S Niijima; K Ishimoto; K Yabuta
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

9.  Mononuclear cell subsets and coronary artery lesions in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Yabuta
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

10.  Intravenous immunoglobulin preparation prevents the production of pro-inflammatory cytokines by modulating NFκB and MAPKs pathways in the human monocytic THP-1 cells stimulated with procalcitonin.

Authors:  Kazuki Murakami; Chiaki Suzuki; Akihiro Fujii; Fujio Kobayashi; Atsushi Nakano; Akihito Kamizono
Journal:  Inflamm Res       Date:  2014-05-29       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.